Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

ConditionNon Small Cell Lung Cancer

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorHunan Province Tumor Hospital

About this trial

This prospective interventional clinical study evaluates the efficacy of nanocrystalline megestrol combined with standard care in improving appetite and weight compared to standard care alone in first-line treatment of NSCLC.

Eligibility criteria

Qualifiers

(1) Voluntarily sign a written ICF. (2) The age at the time of enrollment is ≥18 years old. (3) The physical fitness score of Eastern Tumor Cooperation Organization (ECOG) is 0-2.

Disqualifiers

(1) NSCLC diagnosed with EGFR sensitivity mutation or ALK gene translocation; Histologic presence of a small cell carcinoma component is not allowed to enroll.

Trial design

Treatments tested in this trial

nanocrystalline megestrol oral suspension + PD-1/L1 inhibitor combined with chemotherapy
PD-1/L1 inhibitor combined with chemotherapy

Treatment groups

94 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Hunan Province Tumor Hospital

Lead sponsor

Source ClinicalTrials.gov